
The Spring 2017 edition of Pharmafile is available to read online now!
pharmafile | May 11, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Pharmafocus, pharmafileÂ
The Spring 2017 edition of Pharmafile, our bi-annual market intelligence report for the life sciences industry, is available to read online now!
Throughout its pages you will find a wealth of the latest reports, developments and insights that build a comprehensive picture of the pharma industry as it stands today. We have compiled data and expertise from the industry’s foremost analysis firms and drug manufacturers to help illuminate the path forward throughout the year.
We have collated the latest market analysis from leading research and industry organisations including Deloitte, EvaluatePharma, Clarivate Analytics, BCC Research, the ABPI and the EFPIA. You can also find insight and interviews directly from key figures at major pharmaceutical companies and institutes such as Novartis and Novo Nordisk.
In this issue, we have also included a special Developments in Oncology section, which explores the latest happenings in this revolutionary field with content from the influential organisations including the Institute of Cancer Research, Cancer Research UK, the National Cancer Institute, and more.
Pharmafile also features a valuable directory of key companies and service providers in the industry, ordered by sector and business, to ensure you can stay connected to some of the key players in pharma and life sciences today.
Related Content

Rare disease clinical trials: the urgent need for patients to be heard
Ahead of Clinical Trials Day, Soraya Bekkali, from Alexion, AstraZeneca Rare Disease, highlights the urgent …

Sustainability in pharma
Betsy Goodfellow from Pharmafocus considers the need for sustainable practices in the pharma industry and assesses various …

Pharmafile.com’s top 10 news stories of the week
COVID-19 news has slowed down in the last week, allowing different pharma developments to take …






